For some patients, particularly those with more aggressive disease or a high tumour burden, initiating [177Lu]Lu-PSMA earlier as a standalone treatment may optimise outcomes, while for others, maintaining standard of care (SOC) and introducing radioligand therapy at a later stage may be a more effective approach. This evidence concerns the gene FOLH1 and neoplasm.